Vincristine

Generic Name
Vincristine
Brand Names
Marqibo, Vincasar
Drug Type
Small Molecule
Chemical Formula
C46H56N4O10
CAS Number
57-22-7
Unique Ingredient Identifier
5J49Q6B70F
Background

Vincristine is an antitumor vinca alkaloid isolated from Vinca Rosea. It is marketed under several brand names, many of which have different formulations such as Marqibo (liposomal injection) and Vincasar. Vincristine is indicated for the treatment of acute leukaemia, malignant lymphoma, Hodgkin's disease, acute erythraemia, and acute panmyelosis. vincristine sulfate is often chosen as part of polychemotherapy because of lack of significant bone–marrow suppression (at recommended doses) and of unique clinical toxicity (neuropathy).

Indication

Treatment of acute lymphocytic leukemia (ALL), Hodgkin lymphoma, non-Hodgkin lymphomas, Wilms' tumor, neuroblastoma, rhabdomyosarcoma. Liposomal vincristine is indicated for the treatment of relapsed Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL).

Associated Conditions
Acute Lymphoblastic Leukemia (ALL), Choriocarcinoma, Chronic Lymphocytic Leukemia, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Hepatoblastomas, Hodgkin's Lymphoma, Immune Thrombocytopenia (ITP), Kaposi's Sarcoma, Multiple Myeloma (MM), Neuroblastoma (NB), Non-Hodgkin's Lymphoma (NHL), Ovarian germ cell tumour, Pheochromocytoma, Relapsed Acute Lymphoblastic Leukemia (ALL), Retinoblastoma, Rhabdomyosarcomas, Small Cell Lung Cancer (SCLC), Wilms' tumor, Advanced Thymoma
Associated Therapies
-
Clinical Trials
Related News

Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia

First Posted Date
2019-01-17
Last Posted Date
2024-08-26
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
50
Registration Number
NCT03808610
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

Palbociclib in Combination With Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL)

First Posted Date
2019-01-03
Last Posted Date
2024-08-16
Lead Sponsor
Children's Oncology Group
Target Recruit Count
12
Registration Number
NCT03792256
Locations
🇺🇸

Children's Healthcare of Atlanta - Egleston, Atlanta, Georgia, United States

🇺🇸

Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States

🇺🇸

University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota, United States

and more 16 locations

Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma

First Posted Date
2018-12-26
Last Posted Date
2024-10-17
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
42
Registration Number
NCT03786783
Locations
🇺🇸

Saint Jude Children's Research Hospital, Memphis, Tennessee, United States

🇳🇿

Starship Children's Hospital, Grafton, Auckland, New Zealand

🇦🇺

The Children's Hospital at Westmead, Westmead, New South Wales, Australia

and more 7 locations

A Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell Lymphoma

First Posted Date
2018-11-29
Last Posted Date
2023-10-04
Lead Sponsor
University of Rochester
Target Recruit Count
40
Registration Number
NCT03758989
Locations
🇺🇸

University of Rochester, Rochester, New York, United States

Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17

First Posted Date
2018-11-28
Last Posted Date
2024-04-04
Lead Sponsor
St. Jude Children's Research Hospital
Target Recruit Count
250
Registration Number
NCT03755804
Locations
🇺🇸

Maine Children's Cancer Program, Scarborough, Maine, United States

🇺🇸

St. Jude Affiliate Baton Rouge Clinic (Our Lady of the Lakes Regional Medical Center), Baton Rouge, Louisiana, United States

🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

and more 5 locations

A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma

First Posted Date
2018-09-19
Last Posted Date
2024-12-18
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
117
Registration Number
NCT03677141
Locations
🇺🇸

University of Alabama Birmingham, Birmingham, Alabama, United States

🇺🇸

Banner MD Anderson Cancer Center, Gilbert, Arizona, United States

🇺🇸

University of California; Moores Cancer Center, La Jolla, California, United States

and more 38 locations

Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017

First Posted Date
2018-08-22
Last Posted Date
2023-11-29
Lead Sponsor
Martin Schrappe
Target Recruit Count
5000
Registration Number
NCT03643276
Locations
🇮🇹

AOUC Policlinico Bari, Bari, Italy

🇮🇹

A.O. Papa Giovanni XXIII, Bergamo, Italy

🇮🇹

S.O. Annunziata - A. O. Cosenza, Cosenza, Italy

and more 111 locations

Chidamide Combined With CHOPE Regimen for Peripheral T-cell Lymphoma Patients

First Posted Date
2018-08-06
Last Posted Date
2018-09-04
Lead Sponsor
Peking University
Target Recruit Count
114
Registration Number
NCT03617432
Locations
🇨🇳

Beijing Cancer Hospital, Beijing, China

Ruxolitinib Plus LVP in Patients With R/R ETP-ALL

First Posted Date
2018-08-03
Last Posted Date
2018-08-03
Lead Sponsor
Sichuan University
Target Recruit Count
12
Registration Number
NCT03613428

A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia

First Posted Date
2018-07-17
Last Posted Date
2024-10-31
Lead Sponsor
Takeda
Target Recruit Count
245
Registration Number
NCT03589326
Locations
🇺🇸

Augusta University Georgia Cancer Center, Augusta, Georgia, United States

🇨🇦

Hopital Charles-LeMoyne, Greenfield Park, Quebec, Canada

🇧🇬

University Multiprofile Hospital for Active Treatment Saint Ivan Rilski, Sofia, Sofiya, Bulgaria

and more 89 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy